Brokerages Set Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Target Price at $173.07

Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) have received a consensus recommendation of “Moderate Buy” from the fifteen brokerages that are covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $173.07.

A number of research analysts have commented on the company. Morgan Stanley decreased their price objective on Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating on the stock in a research report on Friday, July 12th. Piper Sandler lowered their target price on shares of Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating for the company in a research note on Thursday, August 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $140.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, August 1st. UBS Group dropped their price objective on shares of Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating on the stock in a report on Tuesday, July 2nd. Finally, StockNews.com raised Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st.

Jazz Pharmaceuticals Stock Down 1.2 %

Shares of NASDAQ:JAZZ opened at $107.14 on Friday. Jazz Pharmaceuticals has a 12 month low of $99.06 and a 12 month high of $137.57. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 1.36. The company’s 50-day moving average price is $109.75 and its two-hundred day moving average price is $112.47. The firm has a market cap of $6.76 billion, a P/E ratio of 22.09, a P/E/G ratio of 1.45 and a beta of 0.58.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Rise Advisors LLC grew its stake in Jazz Pharmaceuticals by 2,255.6% in the 1st quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock valued at $26,000 after buying an additional 203 shares during the last quarter. Versant Capital Management Inc raised its position in shares of Jazz Pharmaceuticals by 13,450.0% in the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock valued at $29,000 after buying an additional 269 shares in the last quarter. Itau Unibanco Holding S.A. bought a new stake in Jazz Pharmaceuticals during the second quarter worth $29,000. EverSource Wealth Advisors LLC lifted its position in shares of Jazz Pharmaceuticals by 55.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 97 shares during the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of Jazz Pharmaceuticals by 65.5% in the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after acquiring an additional 116 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.